Table 1 Psychopathological characteristics at baseline, at 3 months and clinical changes during the follow-up period. Comparison between aripiprazole and risperidone.

From: Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics

 

Total (N = 30)

Statistics

p

Aripiprazole (n = 16)

Risperidone (n = 14)

Statistics

p

Mean

SD

Mean

SD

Mean

SD

CGI

Baseline

6.5

0.6

  

6.56

0.51

6.43

0.65

t = 0.63c

0.532

3 Months

1.8

1.2

  

1.63

1.20

2.00

1.24

  

3-Month change from baseline

−4.7

1.2

z = 4.83a

0.000

−4.90

0.30

−4.47

0.33

F = 0.96d

0.336

YMRS

Baseline

13.8

6.2

  

14.25

7.24

13.29

5.01

t = 0.42c

0.679

3 Months

1.2

2.3

  

1.56

2.63

0.79

1.93

  

3-Month change from baseline

−12.6

6.5

z = 4.78a

0.000

−12.25

0.59

−13.00

0.63

F = 0.75d

0.394

CDSS

Baseline

1.5

3.0

  

2.06

3.82

0.86

1.75

t = 1.08c

0.288

3 Months

1.2

2.3

  

1.19

2.34

1.14

2.25

  

3-Month change from baseline

−0.3

3.7

z = 0.35a

0.724

−0.34

0.59

−0.32

0.63

F = 0.00d

0.985

BPRS

Baseline

70.3

15.0

  

69.06

16.08

71.85

13.95

t = − 0.49c

0.627

3 Months

29.9

7.1

  

29.06

7.07

30.92

7.48

  

3-Month change from baseline

−40.4

15.2

t = 14.32b

0.000

−41.13

1.81

−39.53

2.01

F = 0.35d

0.561

SAPS

Baseline

15.9

4.2

  

15.63

3.50

16.07

4.94

t = − 0.29c

0.775

3 Months

0.6

1.7

  

0.69

1.89

0.71

1.49

  

3-Month change from baseline

−15.4

4.3

t = 19.28b

0.000

−15.14

0.44

−15.12

0.47

F = 0.00d

0.975

SANS

Baseline

4.8

6.9

  

3.47

6.56

5.93

7.43

t = − 0.95c

0.352

3 Months

3.9

6.6

  

4.00

6.47

4.93

7.04

  

3-Month change from baseline

−0.9

5.6

z = 1.14a

0.255

−0.07

1.54

−0.36

1.59

F = 0.02d

0.899

  1. BPRS Brief Psychiatric Rating Scale, CDSS Calgary Depression Rating Scale for Schizophrenia, CGI Clinical Global Impression, SANS Scale for the Assessment of Negative Symptoms, SAPS Scale for the Assessment of Positive Symptoms, YMRS Young Mania Rating Scale
  2. aWilcoxon matched-pairs signed-rank test
  3. bPaired Student’s t-test
  4. cComparison between aripiprazole and risperidone at baseline; unpaired Student’s t-test
  5. dComparison between aripiprazole and risperidone following the antipsychotic treatment, using the total score of the clinical scales at baseline as covariate; analysis of covariance (ANCOVA)